|
Mutation Information
|
Mutation Site
|
A98G |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
doravirine (DOR) |
Literature Information
|
PubMed PMID
|
32180823
|
|
Published Year
|
2020 |
|
Journal
|
Drugs in context |
|
Title
|
Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection. |
|
Author
|
Pham HT,Xiao MA,Principe MA,Wong A,Mesplède T |
|
Evidence
|
Across those clinical isolates (no subtype information was provided), DOR displayed a good antiviral activity with fold changes in EC50<9 against most single mutant viruses, including A98G, E138A/G/K/Q, G190A, K101E/P, K103N/S, L100I, P236L, V106M, V108I, V197D, V90I, Y181C/V, and Y188H/C.
|
|
|
HIV Mutation Detail Information